Revolutionizing Alzheimer’s Diagnosis and Management: The Dawn of Biomarker-Based Precision Medicine
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Alzheimer’s disease (AD), a leading cause of dementia, presents a formidable global health challenge intensified by the aging population. This review encapsulates the evolving landscape of AD diagnosis and treatment with a special focus on the innovative role of fluid biomarkers. Pathologically, AD is marked by amyloid beta (Aβ) plaques and neurofibrillary tangles of hyperphosphorylated tau, which lead to synaptic dysfunction, neuronal loss, and cognitive decline. These pathological changes, commencing decades before symptom onset, underscore the need for early detection and intervention. Diagnosis traditionally relies on clinical assessment, neuropsychological testing, and neuroimaging techniques. However, fluid biomarkers in cerebrospinal fluid and blood, such as various forms of Aβ, total tau, phosphorylated tau, and neurofilament light chain, are emerging as less invasive, cost-effective diagnostic tools. These biomarkers are pivotal for early diagnosis, differential diagnosis, disease progression monitoring, and treatment response evaluation. The treatment landscape is shifting toward personalized medicine, highlighted by advancements in Aβ immunotherapies, such as lecanemab and donanemab. Demonstrating efficacy in phase III clinical trials, these therapies hold promise as tailored treatment strategies based on individual biomarker profiles. The integration of fluid biomarkers into clinical practice represents a significant advance in AD management, providing the potential for early and precise diagnosis, coupled with personalized therapeutic approaches. This heralds a new era in combating this debilitating disease.
Abstract
Alzheimer’s disease (AD), a leading cause of dementia, presents a formidable global health challenge intensified by the aging population. This review encapsulates the evolving landscape of AD diagnosis and treatment with a special focus on the innovative role of fluid biomarkers. Pathologically, AD is marked by amyloid beta (Aβ) plaques and neurofibrillary tangles of hyperphosphorylated tau, which lead to synaptic dysfunction, neuronal loss, and cognitive decline. These pathological changes, commencing decades before symptom onset, underscore the need for early detection and intervention. Diagnosis traditionally relies on clinical assessment, neuropsychological testing, and neuroimaging techniques. However, fluid biomarkers in cerebrospinal fluid and blood, such as various forms of Aβ, total tau, phosphorylated tau, and neurofilament light chain, are emerging as less invasive, cost-effective diagnostic tools. These biomarkers are pivotal for early diagnosis, differential diagnosis, disease progression monitoring, and treatment response evaluation. The treatment landscape is shifting toward personalized medicine, highlighted by advancements in Aβ immunotherapies, such as lecanemab and donanemab. Demonstrating efficacy in phase III clinical trials, these therapies hold promise as tailored treatment strategies based on individual biomarker profiles. The integration of fluid biomarkers into clinical practice represents a significant advance in AD management, providing the potential for early and precise diagnosis, coupled with personalized therapeutic approaches. This heralds a new era in combating this debilitating disease.
참고문헌 (51)
- "2022 Alzheimer’s disease facts and figures", Alzheimers Dement, 18, pp.700~789 (2022)
- GBD 2019 Dementia Forecasting Collaborators, "Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050 : an analysis for the Global Burden of Disease Study 2019", Lancet Public Health, 7, pp.e105~e125 (2022)
- World Alzheimer Report 2015 - The Global Impact of Dementia: An Analysis of Prevalence, Incidence, Cost and Trends, "Prince MJ", Alzheimer’s Disease International, ~ (2015)
- Shin JH, "Dementia epidemiology fact sheet 2022", Ann Rehabil Med, 46, pp.53~59 (2022)
- Shon C, "Health-economic burden of dementia in South Korea", BMC Geriatr, 21, pp.549~ (2021)
- Long JM, "Alzheimer disease : an update on pathobiology and treatment strategies", Cell, 179, pp.312~339 (2019)
- Scheltens P, "Alzheimer’s disease", Lancet, 397, pp.1577~1590 (2021)
- Kwon HS, "Neuroinflammation in neurodegenerative disorders : the roles of microglia and astrocytes", Transl Neurodegener, 9, pp.42~ (2020)
- Selkoe DJ, "The amyloid hypothesis of Alzheimer’s disease at 25 years", EMBO Mol Med, 8, pp.595~608 (2016)
- DeTure MA, "The neuropathological diagnosis of Alzheimer’s disease", Mol Neurodegener, 14, pp.32~ (2019)
- Hanseeuw BJ, "Association of amyloid and tau with cognition in preclinical Alzheimer disease : a longitudinal study", JAMA Neurol, 76, pp.915~924 (2019)
- Aisen PS, "On the path to 2025 : understanding the Alzheimer’s disease continuum", Alzheimers Res Ther, 9, pp.60~ (2017)
- Kim SH, "A therapeutic strategy for Alzheimer’s disease focused on immune-inflammatory modulation", Dement Neurocogn Disord, 18, pp.33~46 (2019)
- van Dyck CH, "Lecanemab in early Alzheimer’s disease", N Engl J Med, 388, pp.9~21 (2023)
- Sims JR, "Donanemab in early symptomatic Alzheimer disease : the TRAILBLAZER-ALZ 2 randomized clinical trial", JAMA, 330, pp.512~527 (2023)
- Cummings J, "Alzheimer’s disease drug development pipeline : 2024", Alzheimers Dement, 10, pp.e12465~ (2024)
- Lennon MJ, "Genetic therapies for Alzheimer’s disease : a scoping review", J Alzheimers Dis, 84, pp.491~504 (2021)
- Stepanichev M, "Gene editing and Alzheimer’s disease : is there light at the end of the tunnel?", Front Genome Ed, 2, pp.4~ (2020)
- Cao Y, "The application of nanotechnology in treatment of Alzheimer’s disease", Front Bioeng Biotechnol, 10, pp.1042986~ (2022)
- Mir Najib Ullah SN, "Nanomedicine in the management of Alzheimer’s disease : state-of-the-art", Biomedicines, 11, pp.1752~ (2023)
- Ward A, "Rate of conversion from prodromal Alzheimer’s disease to Alzheimer’s dementia : a systematic review of the literature", Dement Geriatr Cogn Dis Extra, 3, pp.320~332 (2013)
- Young PN, "Imaging biomarkers in neurodegeneration : current and future practices", Alzheimers Res Ther, 12, pp.49~ (2020)
- Jack CR Jr, "Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade", Lancet Neurol, 9, pp.119~128 (2010)
- Jack CR Jr, "NIA-AA Research Framework: toward a biological definition of Alzheimer’s disease", Alzheimers Dement, 14, pp.535~562 (2018)
- Jack CR Jr, "Revised criteria for diagnosis and staging of Alzheimer’s disease : Alzheimer’s Association Workgroup", Alzheimers Dement, 20, pp.5143~5169 (2024)
- "Roche diagnostics wins nod for Alzheimer’s disease CSF test in Korea" (2023)[URL]
- Park SA, "Promising blood biomarkers for clinical use in Alzheimer’s disease : a focused update", J Clin Neurol, 18, pp.401~409 (2022)
- McGrowder DA, "Cerebrospinal fluid biomarkers of Alzheimer’s disease : Current evidence and future perspectives", Brain Sci, 11, pp.215~ (2021)
- Zetterberg H, "Blood biomarkers for Alzheimer’s disease and related disorders", Acta Neurol Scand, 146, pp.51~55 (2022)
- Hansson O, "Blood biomarkers for Alzheimer’s disease in clinical practice and trials", Nat Aging, 3, pp.506~519 (2023)
- Park SH, "The relationship of soluble TREM2 to other biomarkers of sporadic Alzheimer’s disease", Sci Rep, 11, pp.13050~ (2021)
- Brand AL, "The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease : a literature review", Alzheimers Res Ther, 14, pp.195~ (2022)
- Thijssen EH, "Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration", Nat Med, 26, pp.387~397 (2020)
- Suárez-Calvet M, "Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Aβ pathology are detected", EMBO Mol Med, 12, pp.e12921~ (2020)
- Cai H, "Plasma biomarkers predict Alzheimer’s disease before clinical onset in Chinese cohorts", Nat Commun, 14, pp.6747~ (2023)
- Meyer PF, "Plasma p–tau231, p–tau181, PET biomarkers, and cognitive change in older adults", Ann Neurol, 91, pp.548~560 (2022)
- Palmqvist S, "Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures", Nat Med, 27, pp.1034~1042 (2021)
- Therriault J, "Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer’s disease", Alzheimers Dement, 19, pp.4967~4977 (2023)
- Ashton NJ, "Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology", JAMA Neurol, 81, pp.255~263 (2024)
- Kwon HS, "Predicting amyloid PET positivity using plasma p-tau181 and other blood-based biomarkers", Alzheimers Dement(Amst), 15, pp.e12502~ (2023)
- Kwon HS, "Predicting cognitive stage transition using p-tau181, Centiloid, and other measures", Alzheimers Dement, 19, pp.4641~4650 (2023)
- Bellaver B, "Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer’s disease", Nat Med, 29, pp.1775~1781 (2023)
- Jin M, "Role of neurofilament light chain as a potential biomarker for Alzheimer’s disease : a correlative meta-analysis", Front Aging Neurosci, 11, pp.254~ (2019)
- Gaetani L, "Neurofilament light chain as a biomarker in neurological disorders", J Neurol Neurosurg Psychiatry, 90, pp.870~881 (2019)
- Lee EH, "Serum neurofilament light chain level as a predictor of cognitive stage transition", Alzheimers Res Ther, 14, pp.6~ (2022)
- Guerreiro R, "TREM2 variants in Alzheimer’s disease", N Engl J Med, 368, pp.117~127 (2013)
- Jonsson T, "Variant of TREM2 associated with the risk of Alzheimer’s disease", N Engl J Med, 368, pp.107~116 (2013)
- Ashton NJ, "Plasma levels of soluble TREM2 and neurofilament light chain in TREM2 rare variant carriers", Alzheimers Res Ther, 11, pp.94~ (2019)
- Guo Y, "Characterization of Alzheimer’s tau biomarker discordance using plasma, CSF, and PET", Alzheimers Res Ther, 13, pp.93~ (2021)
- Angioni D, "Can we use blood biomarkers as entry criteria and for monitoring drug treatment effects in clinical trials? A report from the EU", US CTAD task force, 2023, pp.10, 418~425
- Kwon HS, "Monitoring patients with dementia : Insight into global trends, innovations, and future directions", J Clin Neurol, 20, pp.239~240 (2024)